NCT05382819View on ClinicalTrials.gov

A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis

PHASE1TerminatedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

May 16, 2022

Primary Completion Date

February 8, 2023

Study Completion Date

August 11, 2023

Conditions
Atopic Dermatitis Eczema
Interventions
DRUG

FRTX-02 Capsule

DYRK-1A Inhibitor

DRUG

Placebo

Matching Placebo

Trial Locations (1)

QC G1P 0A2

Syneos Health Quebec, Montreal

Sponsors
All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

Innovaderm Research Inc.

OTHER

lead

Fresh Tracks Therapeutics, Inc.

INDUSTRY